Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: We'll give this story a Satisfactory rating in this category since it does mention the $1,000 cost of a colonoscopy and that one of the two at-home screening tests costs about $25. But readers would benefit more by knowing the average costs of the two alternatives, rather than just the cost of one. This story focuses on theavailable methods of colorectal screening, comparing them based on available data, and points out that the two at-home screening kits are comparably effective to the two invasive procedures: sigmoidoscopy and colonoscopy. One of the at-home tests the FIT, or fecal immunochemical test when used, is estimated to prevent 20-23 deaths per thousand people screened, while estimates among those using colonoscopy suggest 22-24 deaths are prevented per thousand people screened. The story is clear in saying that there has been no head-to-head comparative study pitting the techniques against each other. The story gets a Satisfactory rating here since it does mention that with colonoscopy, there's "a small but real risk of harm, such as a perforation" from the screening test. But, as with all screening methods, there is the possibility of false positives or false negatives with the at-home tests which could produce either false confidence or needless worry, not insignificant issues. We would have liked the story even better had it mentioned these factors. The story is quite open with the fact that comparative data assessing the various screening methods against each other are not available, but it strengthens its offerings by citing recommendations from both the US Preventive Services Task Force and the Canadian Task Force on Preventive HealthCare. The recommendations of these independent groups are based on a rigorous evaluation of the highest-quality evidence available. Colon cancer is the second-leading form of cancer-related death in the country; the story does not disease monger. The story quotes three independent sources for information and the recommendations of agencies from two different governments. There is no suggestion that in a story offering a selection of screening techniques, with no one preferred above another, that there is any issue with conflicts of interest. Since this story is totally about the available alternatives for colorectal cancer screening, it easily gets a Satisfactory rating. Both colonoscopy and sigmoidoscopy have been available for years and the at-home screening tests mentioned in the story are said to be available through a patient's doctor's office. These details establish the methods' availability. It also quotes one source asrecommending againstthe use of over-the-counter home screening tests for this disease. The story notes that what's novel here is that the U.S. Preventive Task Force recently finalized their guidelines on colon cancer screening. There is no indication that this story relied on a news release. Claim: You Could Skip Your Colonoscopy If You're Willing To Collect Your Poop

Answer: This story points out that, based on available data, two at-home screening tests appear to be equally effective compared to the more traditional, and more invasive, sigmoidoscopy and colonoscopy. We have only minor quibbles with the storyoverall, it provided an excellent assessment of the at-home test options, particularly the fecal immunochemical test. However, for any story about screening methods, particularly blood tests, we think it's important to include the risks of false-positive and false-negative results, which carry harm. The story didn't go there. Given that the public has reservations about aspects of the invasive screening methods, information suggesting that they might be adequately replaced by non-invasive approaches is important to the public's health. All too often, colonoscopy is promoted as the "gold standard"and no mention is made of effective alternatives. This news storydoes a good job explaining options, and also explores the reasons why so many Americans think that screening with colonoscopy is the best way to be screened for colon cancer and why that attitude is not supported by the evidence and may (in rare cases) be much worse than non-invasive screening methods.

Question: Paragraph: The government has tested around 83,000 people so far for COVID-19, the respiratory disease caused by the virus, Canada's deputy chief public health officer Howard Njoo told reporters. There have been 1,099 confirmed cases. Canada has taken several measures to contain the fast-spreading virus, including closing its border with the United States, which came into effect on Friday night. Trudeau, who is himself in self-isolation after his wife tested positive for COVID-19, told reporters on Saturday the government is ramping up testing to detect as many cases as possible. "The ramping up of testing is increasing at a tremendous pace.... we are getting more equipment for testing. We recognize that broad scale testing is an essential tool in continuing to fight the spread of this disease," Trudeau told reporters. There are around 5,000 ventilators across the country, Njoo said. He also said Canada is making efforts to bring home stranded citizens, and an Air Canada (AC.TO) plane is in the process of repatriating citizens from Morocco. He named Peru and Spain as two potential countries from which Canada was working with airlines to bring home stranded citizens. But Trudeau said the travel restriction put in place by many countries mean not every Canadian stuck overseas would be able to come home immediately. "We are going to ask people to stay safe, make smart choices and do the best they can in a situation that is unprecedented, exceptional and very difficult," Trudeau said. Canada's foreign minister Francois-Philippe Champagne estimated there are ten of thousands of Canadians overseas. Trudeau's government has pledged C$27 billion ($18.6 billion) to help the economy amid the virus outbreak, which could blow out the fiscal deficit and lead to higher government borrowing by nearly 40%, according to Reuters calculations. "We have heard a wide range of estimates from economists and banks about how bad it is going to get. The only thing they seem to agree on is, it is going to get very bad. Fortunately, Canada is in an extremely strong fiscal position... and that gives us room to inject money into people's pocket," Trudeau added. Meanwhile, Canada's decision to turn back asylum seekers who walk over the U.S.-Canada border has been criticized by advocates. "The government's decision... ignores the recommendations of the World Health Organization and isn't part of a sound pandemic management plan," said Nazila Bettache, with the Caring for Social Justice Collective. She said asylum seekers will cross by other means that are less controlled and will not have access to proper safety measures, such as a 14-day quarantine. Claim: Canada's coronavirus death toll rises to 13 as repatriation efforts step up.

Answer: Canada's death toll from the coronavirus rose to 13 on Saturday, and the country stepped up efforts to repatriate Canadians stranded overseas as Prime Minister Justin Trudeau called the situation "unprecedented, exceptional and very difficult."

Question: Paragraph: Sangamo shares jumped as much as 30 percent to a six-year high of $17.73 on the Nasdaq on Thursday morning. Biogen will use Sangamo's genome-editing technology to develop drugs targeting sickle cell disease and beta-thalassemia. It will provide Sangamo $20 million upfront and reimburse costs related to research and development. Sangamo will also be eligible for milestone payments of about $300 million, as well as double digit royalties on product sales. The upfront payment and the terms of the milestone payments and the double digit royalties were pretty high, Wedbush analyst Liana Moussatos said. "The deal terms are very lucrative for a pre-clinical platform. So I think Biogen must have been impressed with the pre-clinical data that Sangamo presented last month." Sangamo presented the data last month at the annual meeting of the American Society of Hematology. The company will be responsible for research and development for the first proof-of-concept study for beta-thalassemia, according to Thursday's deal. Beta-thalassemia impairs the body's ability to produce hemoglobin, the protein in red blood cells (RBC). Sickle cell disease changes the shape RBCs, tending to block blood flow. Moussatos said Sangamo also had a promising HIV program, with a patient to stay with undetectable viral load for six months. "That's another viable treatment and I won't be surprised if they announce another partnership for that," Moussatos said. Claim: Sangamo to develop blood disorder drugs with Biogen.

Answer:
Sangamo Biosciences Inc said it would collaborate with Biogen Idec Inc to develop treatments for a group of inherited blood disorders in a deal for up to $320 million.